* Safety and efficacy in pediatric patients 12 years and older was established in a randomized double-blind, placebo-controlled, multicenter trial, which included 11 pediatric patients 12 to 16 years exposed to Fycompa; an additional 6 patients were treated with Fycompa in the open label extension of the study * Safety and effectiveness in pediatric patients less than 12 years of age have not been established * Adverse reactions were similar to those observed in adults * Information on dosing, PK, clinical studies, and adverse reactions * New indication
|